EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network homepage

Menu

Members

Sophia Karagiannis

Name of the laboratory

Professor of Translational Cancer Immunology and Immunotherapy
St. John's Institute of Dermatology
School of Basic & Medical Biosciences
King's College London, UK

Research Group Members

Members: St. John's Institute of Dermatology
Leader
Professor Sophia N Karagiannis sophia.karagiannis@kcl.ac.uk
Members
Dr Rebecca Adams (NIHR Clinical Lecturer & Dermatology Registrar) rebecca.1.adams@kcl.ac.uk
Anishaa Balaji (Research Assistant) anishaa.2.balaji@kcl.ac.uk
Dr Heather Bax (Postdoctoral Research Fellow) heather.bax@kcl.ac.uk
Ms Lucy Booth (MRC PhD student) lucy.booth@kcl.ac.uk
Dr Jitesh Chauhan (Research Associate) jitesh.chauhan@kcl.ac.uk
Sammy Chen (PhD Student) sammy.xy.chen@kcl.ac.uk
Dr Alicia Chenoweth (BCN Postdoctoral Research Associate) alicia.chenoweth@kcl.ac.uk
Dr Anthony Cheung (BCN Postdoctoral Research Associate) anthony.cheung@kcl.ac.uk
Ms Yi Liu (PhD Student) yi.8.liu@kcl.ac.uk
Dr Alexandra M McCraw (Postdoctoral Research Associate) alexandra.mccraw@kcl.ac.uk
Dinethri Patel (PhD Student) dinethri.1.patel@kcl.ac.uk
Jakub Zydron (MRC iCASE PhD Student) jakub.zydron@kcl.ac.uk

Summary of research

Our main research interests centre on designing antibody therapies for solid tumours such as melanoma, ovarian and breast carcinomas. Our antibody discovery pathway is informed through dissecting the B cell and antibody humoral immune responses in patients with solid tumours as well as investigating the tumour-targeting mechanisms of IgE and Fc-engineered IgG class antibodies and Th2 responses in cancer. Patient-derived antibodies and B cell responses are examined as potential biomarkers, with a view of developing stratified medicine approaches and patient-focused treatments. We are presently developing a pipeline of antibodies and antibody-drug conjugates (ADCs) for cancer therapy. Our group is the first worldwide to design and translate anti-cancer IgE class antibodies from concept to clinical trials and to commercialisation. We have co-founded the AllergoOncology field, focused on Th2 and IgE immunity in the interphase between allergy and cancer, to which our research on IgE, IgG4 and B cell immune responses in cancer has contributed key advances.

Research activities

Our laboratory’s activities are focused on the discovery and evaluation of monoclonal antibodies for clinically challenging solid tumours such as melanoma, ovarian and breast carcinomas and on dissecting immune responses to cancer with particular focus on B cells and the antibodies they produce. Major research streams in our laboratory include: a) dissecting humoral responses and mechanisms of Th2-biased inflammation in tumours; b) interrogating patient humoral responses as potential biomarkers to aid stratification and with a view of developing patient-focused treatments; c) designing antibodies with potent effector functions and the interactions of antibodies with immune cells such as monocytes/macrophages, NK cells and basophils; d) elucidating antibody mechanisms of action in disease-relevant models.

Part of our research focuses on the nature and functions of B cells and antibodies in tumour immunity, particularly on tumour-resident and tumour-reactive B cell subsets and on antibody expression in tissues and the circulation. We have placed particular emphasis on antibody subclasses with immunosuppressive functions such as IgG4 which may suppress effector cell functions and block cytotoxic antibodies from eradicating cancer. We have demonstrated that antibodies produced in patients with melanoma can recognize and attack tumour cells. Despite producing antibodies recognising tumour cells, patients’ immune systems are mostly ineffective in restricting cancer growth. We have also shown that the tissue environment in tumours provides specific conditions, including production of cytokines like IL-10, which favour expression of IgG4 antibodies, resulting in antibody-mediated immune responses with reduced potency. We furthermore study patient-derived antibodies and B cell responses as potential biomarkers with a view of predicting clinical outcomes and developing patient-focused treatments.

Another key area of research relates to evaluating the impact of antibody clone and isotype on the therapeutic efficacy of tumour antigen-specific antibodies and antibody-drug conjugates (ADCs). Our research suggests that compared to IgG, aspects of IgE biology are potentially suited to cancer therapy, including a higher binding affinity for Fc receptors, and the ability to activate different populations of potent effector cells normally present in tumour tissues to kill tumour cells. Our studies provide an insight into the diversity of mechanisms different classes of antibodies employ to activate immune effector cells such as monocytes/macrophages to target and kill tumours. Our most advanced agent, MOv18 IgE, recognising the α isoform of Folate Receptor, a tumour-associated antigen expressed almost exclusively in tissue cancers such as those of the ovary and subsets of breast cancers, has completed Phase I clinical testing (NCT02546921) and is currently undergoing a Phase Ib (NCT06547840) clinical trial sponsored by Epsilogen Ltd., a King’s College London spinout company founded by Prof. Sophia Karagiannis. We continue to perform safety, efficacy, potency and mechanistic studies on this agent and we are developing a pipeline of IgE immunotherapeutic agents directed at cancer-associated antigens.

To interrogate antibody potency and mechanisms of action in recruiting, re-educating and activating human effector cell subsets against a range of target antigens, we are developing disease-relevant models featuring engraftment of different components of human immunity. Working with collaborating laboratories and biotechnology partners, we are developing novel antibody glyco-engineering approaches, antibody-drug conjugates, antibodies for further development in imaging studies and for cancer therapy, with the aim of expediting promising therapies and diagnostic tools from the laboratory bench to the patient bedside.

Grant support

Our research has been supported through project and programme grants by Cancer Research UK and the CR UK New Agents Committee, Breast Cancer Now, the British Skin Foundation, Innovate UK, the National Institute for Health and Care Research (NIHR), the Academy of Medical Sciences, the Biotechnology and Biological Sciences Research Council (BBSRC), the Medical Research Council, Wellbeing of Women, Worldwide Cancer Research and others. We work with several industrial partners to progress world-first discoveries and innovations in antibody and ADC design towards clinical testing and application for patient benefit.

Publications (2021-present)

  • Esapa B, Liu Y, Chenoweth AM, Stoker K, Łabędź N, Romero-Clavijo P, Ilieva KM, Trendell J, Navarro-Llinas B, Suriawinata E, Butcher T, Wang N, Grandits M, Palhares LCGF, McCraw A, Crescioli S, Johansson A, Irshad S, Grigoriadis A, Gazinska P, Tsoka S, Chudasama V, Baker JR, Tutt ANJ, Cheung A, Thurston DE, Karagiannis SN. An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer. NPJ Precis Oncol. 2026 Mar 7. doi: 10.1038/s41698-026-01341-0.
  • Booth L, Chen X, Stoker K, McCraw A, Tahiri M, Wu Y, Geh JLC, MacKenzie Ross AD, Lloyd-Hughes H, Lacy KE, Whittaker S, Jacków-Malinowska J, Van Hemelrijck M, Tull TJ, Tsoka S, Karagiannis SN. Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: A scoping review. Br J Dermatol. 2026 Feb 26:ljag074. doi: 10.1093/bjd/ljag074.
  • Booth L, Mahmood M, Chen X, Jacków-Malinowska J, Tsoka S, Tull TJ, Karagiannis SN. B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy. Oncoimmunology. 2026 Dec 31;15(1):2638620. doi: 10.1080/2162402X.2026.2638620.
  • Zydron J, Balaji A, Chauhan J, Alder J, Chen X, Wiegman AMF, Poli A, Jacków-Malinowska J, Cheeseman J, Spencer DIR, McDonnell J, Spicer J, McCraw AJ, Karagiannis SN. AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes. Clin Exp Allergy. 2026 Feb 11. doi: 10.1111/cea.70234.
  • Ntostoglou K, Christodoulopoulos G, Stoker K, Descarpentrie J, Xagara A, Chatzidaki D, Anastasopoulou V, Nikas IP, Ieronimaki AI, Booth L, Tsoka S, Vamvakaris I, Klinakis A, Patsea E, Karagiannis SN, Panayiotides IG, Frisan T, Georgoulias V, Kotsakis A, Pateras IS. Immunophenotyping TCF1-expressing TILs: spatial profiling and prognostic value in operable non-small cell lung cancer. Front Immunol. 2026 Jan 22;17:1731337. doi: 10.3389/fimmu.2026.1731337.
  • Balaji A, Karagiannis SN, McCraw AJ. Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort. Allergy. 2026 Feb 5. doi: 10.1111/all.70249.
  • Sieh JYX, Osborn G, Karagiannis SN, Capon F. IL-36γ signalling promotes a proinflammatory macrophage state that is associated with reduced lipid uptake. Cytokine. 2026 Feb;198:157091. doi: 10.1016/j.cyto.2025.157091.
  • George G, Rowley M, Coolen ACC, Santa Olalla A, Hammar N, Feychting M, Karagiannis SN, Enting D, Van Hemelrijck M. ESMO Real World Data Digit Oncol. 2025 Jun 3;8:100156. doi: 10.1016/j.esmorw.2025.100156.
  • Naidu V, Jain HA, Yalcinkaya A, Charavanamuttu Y, Biswas D, Ali N, Mee JB, Chauhan J, Semkova K, Benton EC, Karagiannis SN, Setterfield J, Groves RW, Tull TJ. Clinical correlation of anti-desmoglein antibody dynamics in pemphigus treated with rituximab. Front Immunol. 2025 Dec 12;16:1713987. doi: 10.3389/fimmu.2025.1713987.
  • Chenoweth AM, Cheung A, Chauhan J, Adams R, Osborn G, Stoker K, Grandits M, Laddach R, Trendell J, Navarro-Llinas B, Suriawinata E, Gross A, Clarke A, Brown L, Cserny J, Moise L, Jatiani S, McCraw A, Esapa B, Haider S, Quist J, Ilieva KM, Davies AM, Romero-Clavijo P, Sénard T, Cheeseman J, Gardner RA, Spencer DIR, Tsoka S, Irshad S, McDonnell JM, Grigoriadis A, Tutt ANJ, Karagiannis SN. An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer. Cancer Res. 2025 Nov 14;85(23):4521-4540. doi: 10.1158/0008-5472.CAN-24-3174.
  • Bianchini R, Escolar-Peña A, Pick V, Poli A, Adams R, Basilio J, Cari L, Chauhan J, Chivato T, Vecillas LL, Delgado-Dolset MI, Escribese MM, Grandits M, Bax HJ, Martín-Antoniano IA, Martín-Cruz L, Mayerhofer H, Michelucci A, Nocentini G, Osborn G, Pablo-Torres C, Palomares O, Pascal M, Radzikowska U, Rohr-Udilova N, Sokolowska M, Bergmann C, Jensen-Jarolim E, Karagiannis SN, Rebollido-Rios R, Izquierdo E. Molecular Signatures and Functional Pathways of Human Monocytes and Macrophages in Allergy: An EAACI AllergoOncology Scoping Review. Allergy. 2025 Oct;80(10):2710-2725. doi: 10.1111/all.16672.
  • Monroy-Iglesias MJ, Thavarajah R, Beckmann K, Josephs DH, Irshad S, Karagiannis SN, Van Hemelrijck M, Santaolalla A. Effects of vitamin D on COVID-19 risk and hospitalisation in the UK biobank. PLoS One. 2025 Jul 18;20(7):e0328232. doi: 10.1371/journal.pone.0328232.
  • Ng JCF, Chenoweth A, De Sciscio ML, Grandits M, Cheung A, Chu T, McCraw A, Chauhan J, Liu Y, Guo D, Patel S, Kosmider A, Iancu D, Karagiannis SN, Fraternali F. Tuning antibody stability and function by rational designs of framework mutations. MAbs. 2025 Dec;17(1):2532117. doi: 10.1080/19420862.2025.2532117.
  • Armstrong GB, Graham H, Cheung A, Montaseri H, Burley GA, Karagiannis SN, Rattray Z. Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers. Adv Drug Deliv Rev. 2025 Sep;224:115648. doi: 10.1016/j.addr.2025.115648.
  • Pascal M, Chauhan J, Knol E, Bianchini R, Castells M, De Las Vecillas L, Hartmann K, Izquierdo E, Jappe U, Jimenez-Rodriguez TW, Levi-Schaffer F, Mayorga C, Poli A, Redegeld F, Santos AF, Jensen-Jarolim E, Bergmann C, Karagiannis SN, Bax HJ. Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology: An EAACI Position Paper. Allergy. 2025 Aug;80(8):2097-2112. doi: 10.1111/all.16607.
  • Willsmore ZN, Booth L, Patel A, Di Meo A, Prassas I, Chauhan J, Wu Y, Fitzpartick A, Stoker K, Kapiris M, Biswas D, Perucha E, Whittaker S, Tsoka S, Diamandis EP, Middleton GW, Tull TJ, Papa S, Lacy KE, Karagiannis SN. Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma. J Immunother Cancer. 2025 May 31;13(5):e011682.
  • Considine P, Punnabhum P, Davidson CG, Armstrong GB, Kreiner M, Bax HJ, Chauhan J, Spicer J, Josephs DH, Karagiannis SN, Halbert G, Rattray Z. Assessment of biophysical properties of the first-in-class anti-cancer IgE antibody drug MOv18 IgE demonstrates monomeric purity and stability. MAbs. 2025 Dec;17(1):2512211. doi: 10.1080/19420862.2025.2512211.
  • Grandits M, Palhares LCGF, Macleod O, Devlin J, Amin OE, Birtley J, Partington L, Wilson T, Hardaker E, Karagiannis SN, Bax HJ, FitzGerald K. Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality. MAbs. 2025 Dec;17(1):2502673. doi: 10.1080/19420862.2025.2502673.
  • Osborn G, López-Abente J, Adams R, Laddach R, Grandits M, Bax HJ, Chauhan J, Pellizzari G, Nakamura M, Stavraka C, Chenoweth A, Palhares LCGF, Evan T, Lim JHC, Gross A, Moise L, Jatiani S, Figini M, Bianchini R, Jensen-Jarolim E, Ghosh S, Montes A, Sayasneh A, Kristeleit R, Tsoka S, Spicer J, Josephs DH, Karagiannis SN. Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction. Nat Commun. 2025 Apr 10;16(1):2903. doi: 10.1038/s41467-025-57870-y.
  • Grandits M, Palhares LCGF, Osborn G, Chauhan J, Stoker K, Sow HS, Adams R, McCraw AJ, Chenoweth A, Vlasova S, López-Abente J, Ilieva KM, Birtley J, Tsoka S, Hardaker E, FitzGerald K, Karagiannis SN, Bax HJ. Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors. J Immunother Cancer. 2025 Mar 12;13(3):e010945. doi: 10.1136/jitc-2024-010945.
  • Stavraka C, Chauhan J, Crescioli S, McSweeney SM, Pope A, Gillett C, Di Meo A, Prassas I, Laddach R, Stoker K, McCraw AJ, Adams R, Tull TJ, Naban N, Willsmore Z, Semkova KV, Grattan CEH, McGrath J, Till SJ, Corrigan CJ, Kristeleit R, Tsoka S, Diamandis EP, Lacy KE, Pinder S, Josephs DH, Spicer J, Bax HJ, Karagiannis SN. Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha. Allergy. 2025 Aug;80(8):2225-2239. doi: 10.1111/all.16514.
  • Liu Y, Chen X, Evan T, Esapa B, Chenoweth A, Cheung A, Karagiannis SN. Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age. MAbs. 2025 Dec;17(1):2470309. doi: 10.1080/19420862.2025.2470309.
  • Maiques O, Sallan MC, Laddach R, Pandya P, Varela A, Crosas-Molist E, Barcelo J, Courbot O, Liu Y, Graziani V, Arafat Y, Sewell J, Rodriguez-Hernandez I, Fanshawe B, Jung-Garcia Y, Imbert PR, Grasset EM, Albrengues J, Santacana M, Macià A, Tarragona J, Matias-Guiu X, Marti RM, Tsoka S, Gaggioli C, Orgaz JL, Fruhwirth GO, Wallberg F, Betteridge K, Reyes-Aldasoro CC, Haider S, Braun A, Karagiannis SN, Elosegui-Artola A, Sanz-Moreno V. Matrix mechano-sensing at the invasive front induces a cytoskeletal and transcriptional memory supporting metastasis. Nat Commun. 2025 Feb 14;16(1):1394. doi: 10.1038/s41467-025-56299-7.
  • Palhares LCGF, Grandits M, Stoker K, Chauhan J, Sow HS, Fruhwirth GO, Tsoka S, Birtley J, Partington L, Wilson T, Hardaker E, Karagiannis SN, Bax HJ, FitzGerald K. An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities. J Exp Clin Cancer Res. 2025 Feb 12;44(1):49. doi: 10.1186/s13046-025-03319-5.
  • Bax HJ, Chauhan J, McCraw AJ, Grandits M, Stavraka C, Lentfer H, Hillyer T, Carroll S, Vigor K, Selkirk C, Figini M, Cheeseman J, Urbanowicz PA, Gardner RA, Spencer DIR, Westwood N, Mellor S, Spicer J, Josephs DH, Karagiannis SN. Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production. MAbs. 2025 Dec;17(1):2451295. doi: 10.1080/19420862.2025.2451295.
  • Subramanian P, Sayegh S, Laphanuwat P, Devine OP, Fantecelle CH, Sikora J, Chambers ES, Karagiannis SN, Gomes DCO, Kulkarni A, Rustin MHA, Lacy KE, Akbar AN. Multiple outcomes of the germline p16INK4a mutation affecting senescence and immunity in human skin. Aging Cell. 2025 Feb;24(2):e14373. doi: 10.1111/acel.14373.
  • Chen X, Habib S, Alexandru M, Chauhan J, Evan T, Troka JM, Rahimi A, Esapa B, Tull TJ, Ng WZ, Fitzpatrick A, Wu Y, Geh JLC, Lloyd-Hughes H, Palhares LCGF, Adams R, Bax HJ, Whittaker S, Jacków-Malinowska J, Karagiannis SN. Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma. Cancers (Basel). 2024 Sep 25;16(19):3260. doi: 10.3390/cancers16193260.
  • McCraw AJ, Palhares LCGF, Hendel JL, Gardner RA, Santaolalla A, Crescioli S, McDonnell J, Van Hemelrijck M, Chenoweth A, Spencer DIR, Wagner GK, Karagiannis SN. IgE glycosylation and impact on structure and function: A systematic review. Allergy. 2024 Oct;79(10):2625-2661. doi: 10.1111/all.16259.
  • Pascal M, Bax HJ, Bergmann C, Bianchini R, Castells M, Chauhan J, De Las Vecillas L, Hartmann K, Álvarez EI, Jappe U, Jimenez-Rodriguez TW, Knol E, Levi-Schaffer F, Mayorga C, Poli A, Redegeld F, Santos AF, Jensen-Jarolim E, Karagiannis SN. Granulocytes and mast cells in AllergoOncology-Bridging allergy to cancer: An EAACI position paper. Allergy. 2024 Sep;79(9):2319-2345. doi: 10.1111/all.16246.
  • Pham TT, Chenoweth A, Patel N, Banu A, Osborn G, Blower PJ, Karagiannis SN, Ma MT. In Vivo PET Imaging of 89Zr-Labeled Natural Killer Cells and the Modulating Effects of a Therapeutic Antibody. J Nucl Med. 2024 Jul 1;65(7):1035-1042. doi: 10.2967/jnumed.124.267876.
  • Cheung A, Chenoweth AM, Johansson A, Laddach R, Guppy N, Trendell J, Esapa B, Mavousian A, Navarro-Llinas B, Haider S, Romero-Clavijo P, Hoffmann RM, Andriollo P, Rahman KM, Jackson P, Tsoka S, Irshad S, Roxanis I, Grigoriadis A, Thurston DE, Lord CJ, Tutt ANJ, Karagiannis SN. Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. Clin Cancer Res. 2024 Aug 1;30(15):3298-3315. doi: 10.1158/1078-0432.CCR-23-3110.
  • Bridge S, Karagiannis SN, Borsini A. The complex role of the chemokine CX3CL1/Fractalkine in major depressive disorder: A narrative review of preclinical and clinical studies. Brain Behav Immun Health. 2024 Apr 28;38:100778. doi: 10.1016/j.bbih.2024.100778.
  • Santucci C, Alexandru M, Chen X, Mellerio JE, Karagiannis SN, Jacków-Malinowska J. Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Hum Immunol. 2024 May;85(3):110805. doi: 10.1016/j.humimm.2024.110805.
  • Habib S, Osborn G, Willsmore Z, Chew MW, Jakubow S, Fitzpatrick A, Wu Y, Sinha K, Lloyd-Hughes H, Geh JLC, MacKenzie-Ross AD, Whittaker S, Sanz-Moreno V, Lacy KE, Karagiannis SN, Adams R. Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma. Expert Rev Clin Immunol. 2024 Aug;20(8):895-911. doi: 10.1080/1744666X.2024.2326626.
  • Turner MC, Radzikowska U, Ferastraoaru DE, Pascal M, Wesseling P, McCraw A, Backes C, Bax HJ, Bergmann C, Bianchini R, Cari L, de Las Vecillas L, Izquierdo E, Lind-Holm Mogensen F, Michelucci A, Nazarov PV, Niclou SP, Nocentini G, Ollert M, Preusser M, Rohr-Udilova N, Scafidi A, Toth R, Van Hemelrijck M, Weller M, Jappe U, Escribese MM, Jensen-Jarolim E, Karagiannis SN, Poli A. AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus-A joint EAACI-EANO position paper. Allergy. 2024 Jun;79(6):1419-1439. doi: 10.1111/all.15994.
  • Santaolalla A, Bax HJ, Chauhan J, Josephs DH, Van Hemelrijck M, Karagiannis SN. Protective effects of allergic diseases in COVID-19 outcomes: A retrospective cohort study in UK Biobank in the general population and in patients with cancer. Clin Exp Allergy. 2024 Apr;54(4):297-299. doi: 10.1111/cea.14445.
  • Spicer J, Basu B, Montes A, Banerji U, Kristeleit R, Miller R, Veal GJ, Corrigan CJ, Till SJ, Figini M, Canevari S, Barton C, Jones P, Mellor S, Carroll S, Selkirk C, Nintos G, Kwatra V, Funingana IG, Doherty G, Gould HJ, Pellizzari G, Nakamura M, Ilieva KM, Khiabany A, Stavraka C, Chauhan J, Gillett C, Pinder S, Bax HJ, Josephs DH, Karagiannis SN. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial. Nat Commun. 2023 Jul 25;14(1):4180. doi: 10.1038/s41467-023-39679-9.
  • Crescioli S, Correa I, Ng J, Willsmore ZN, Laddach R, Chenoweth A, Chauhan J, Di Meo A, Stewart A, Kalliolia E, Alberts E, Adams R, Harris RJ, Mele S, Pellizzari G, Black ABM, Bax HJ, Cheung A, Nakamura M, Hoffmann RM, Terranova-Barberio M, Ali N, Batruch I, Soosaipillai A, Prassas I, Ulndreaj A, Chatanaka MK, Nuamah R, Kannambath S, Dhami P, Geh JLC, MacKenzie Ross AD, Healy C, Grigoriadis A, Kipling D, Karagiannis P, Dunn-Walters DK, Diamandis EP, Tsoka S, Spicer J, Lacy KE, Fraternali F, Karagiannis SN. B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma. Nat Commun. 2023 Jun 8;14(1):3378. doi: 10.1038/s41467-023-39042-y.
  • Amiri Souri E, Chenoweth A, Karagiannis SN, Tsoka S. Drug repurposing and prediction of multiple interaction types via graph embedding. BMC Bioinformatics. 2023 May 17;24(1):202. doi: 10.1186/s12859-023-05317-w.
  • Chauhan J, Grandits M, Palhares LCGF, Mele S, Nakamura M, López-Abente J, Crescioli S, Laddach R, Romero-Clavijo P, Cheung A, Stavraka C, Chenoweth AM, Sow HS, Chiaruttini G, Gilbert AE, Dodev T, Koers A, Pellizzari G, Ilieva KM, Man F, Ali N, Hobbs C, Lombardi S, Lionarons D, Gould HJ, Beavil AJ, Geh JLC, MacKenzie Ross AD, Healy C, Calonje E, Downward J, Nestle FO, Tsoka S, Josephs DH, Blower PJ, Karagiannis P, Lacy KE, Spicer J, Karagiannis SN, Bax HJ. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4. Nat Commun. 2023;14(1):2192. doi: 10.1038/s41467-023-37811-3.
  • Esapa B, Jiang J, Cheung A, Chenoweth A, Thurston DE, Karagiannis SN. Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers (Basel). 2023 Mar 19;15(6):1845.
  • Bax HJ, Chauhan J, Stavraka C, Santaolalla A, Osborn G, Khiabany A, Grandits M, López-Abente J, Palhares LCGF, Chan Wah Hak C, Robinson A, Pope A, Woodman N, Naceur-Lombardelli C, Malas S, Coumbe JEM, Nakamura M, Laddach R, Mele S, Crescioli S, Black AM, Lombardi S, Canevari S, Figini M, Sayasneh A, Tsoka S, FitzGerald K, Gillett C, Pinder S, Van Hemelrijck M, Kristeleit R, Ghosh S, Montes A, Spicer J, Karagiannis SN, Josephs DH. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer. 2023 Jan;128(2):342-353.
  • Patel AJ, Willsmore ZN, Khan N, Richter A, Naidu B, Drayson MT, Papa S, Cope A, Karagiannis SN, Perucha E, Middleton GW. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nat Commun. 2022 Jun 7;13(1):3148.
  • Crescioli S, White AL, Karagiannis SN. Special Issue "Antibody Engineering for Cancer Immunotherapy". Antibodies (Basel). 2022 Apr 15;11(2):29.
  • Monroy-Iglesias MJ, Crescioli S, Beckmann K, Le N, Karagiannis SN, Van Hemelrijck M, Santaolalla A. Antibodies as biomarkers for cancer risk: A systematic review. Clin Exp Immunol. 2022 Apr 4:uxac030. doi: 10.1093/cei/uxac030.
  • Amiri Souri E, Laddach R, Karagiannis SN, Papageorgiou LG, Tsoka S. Novel drug-target interactions via link prediction and network embedding. BMC Bioinformatics. 2022 Apr 4;23(1):121.
  • Adams R, Coumbe JEM, Coumbe BGT, Thomas J, Willsmore Z, Dimitrievska M, Yasuzawa-Parker M, Hoyle M, Ingar S, Geh JLC, MacKenzie Ross AD, Healy C, Papa S, Lacy KE, Karagiannis SN. BRAF inhibitors and their immunological effects in malignant melanoma. Expert Rev Clin Immunol. 2022 Apr;18(4):347-362.
  • Chauhan J, Stavraka C, Grandits M, Palhares LCGF, Josephs DH, Lacy KE, Spicer J, Bax HJ, Karagiannis SN. Clinical and Translational Significance of Basophils in Patients with Cancer. Cells. 2022 Jan 27;11(3):438.
  • Bergmann C, Poli A, Agache I, Bianchini R, Bax HJ, Castells M, Crescioli S, Dombrowicz D, Ferastraoaru D, Fiebiger E, Gould HJ, Hartmann K, Izquierdo E, Jordakieva G, Josephs DH, Jutel M, Levi-Schaffer F, de Las Vecillas L, Lotze MT, Osborn G, Pascal M, Redegeld F, Rosenstreich D, Roth-Walter F, Schmidt-Weber C, Shamji M, Steveling EH, Turner MC, Untersmayr E, Jensen-Jarolim E, Karagiannis SN. AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper. Allergy. 2022 Feb 13. doi: 10.1111/all.15255.
  • Karagiannis P, Correa I, Chauhan J, Cheung A, Dominguez-Rodriguez D, Terranova-Barberio M, Harris RJ, Crescioli S, Spicer J, Bokemeyer C, Lacy KE, Karagiannis SN. Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. Clin Exp Immunol. 2022 Jan 28;207(1):84-94.
  • Egbuniwe IU, Harris RJ, Nakamura M, Nestle FO, Akbar AN, Karagiannis SN, Lacy KE. B Lymphocytes Accumulate and Proliferate in Human Skin at Sites of Cutaneous Antigen Challenge. J Invest Dermatol. 2022 Mar;142(3 Pt A):726-731.e4.
  • Harris RJ, Willsmore Z, Laddach R, Crescioli S, Chauhan J, Cheung A, Black A, Geh JLC, MacKenzie Ross AD, Healy C, Tsoka S, Spicer J, Kacy KE, Karagiannis SN. Enriched circulating and tumor-resident TGFβ regulatory B cells in patients with melanoma promote FOXP3+ Tregs. Oncoimmunology. 2022 Jul 28;11(1):2104426.
  • McCraw AJ, Gardner RA, Davies AM, Spencer DIR, Grandits M, Wagner GK, McDonnell JM, Karagiannis SN, Chenoweth A, Crescioli S. Generation and Characterization of Native and Sialic Acid-Deficient IgE. Int J Mol Sci. 2022 Nov 3;23(21):13455.
  • Handford J, Chen M, Rai R, Moss CL, Enting D, Peat N, Karagiannis SN, Van Hemelrijck M, Russell B. Is There a Role for Exercise When Treating Patients with Cancer with Immune Checkpoint Inhibitors? A Scoping Review. Cancers (Basel). 2022 Oct 14;14(20):5039.
  • Adams R, Osborn G, Mukhia B, Laddach R, Willsmore Z, Chenoweth A, Geh JLC, MacKenzie Ross AD, Healy C, Barber L, Tsoka S, Sanz-Moreno V, Lacy KE, Karagiannis SN. Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies. Oncoimmunology. 2022 Oct 3;11(1):2127284.
  • Monroy-Iglesias MJ, Tremble K, Russell B, Moss C, Dolly S, Sita-Lumsden A, Cortellini A, Pinato DJ, Rigg A, Karagiannis SN, Van Hemelrijck M. Long-term effects of COVID-19 on cancer patients: the experience from Guy's Cancer Centre. Future Oncol. 2022 Oct;18(32):3585-3594.
  • Cheung A, Chenoweth AM, Quist J, Sow HS, Malaktou C, Ferro R, Hoffmann RM, Osborn G, Sachouli E, French E, Marlow R, Lacy KE, Papa S, Grigoriadis A, Karagiannis SN. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. Cancers (Basel). 2022 Jul 11;14(14):3361.
  • Karagiannis SN, Arnold JN. Immune cell-antibody interactions in health and disease. Clin Exp Immunol. 2022 Jul 22;209(1):1-3.
  • Osborn G, Stavraka C, Adams R, Sayasneh A, Ghosh S, Montes A, Lacy KE, Kristeleit R, Spicer J, Josephs DH, Arnold JN, Karagiannis SN. Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. Clin Exp Immunol. 2021 Nov 22:uxab020. doi: 10.1093/cei/uxab020.
  • Li S, McCraw AJ, Gardner RA, Spencer DIR, Karagiannis SN, Wagner GK. Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors. Antibodies (Basel). 2021 Nov 4;10(4):44.
  • Adams R, Moser B, Karagiannis SN, Lacy KE. Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician. Cancers (Basel). 2021 Nov 10;13(22):5625.
  • Chen M, Raj R, Fox L, Moss CL, George G, Karagiannis SN, Enting D, Joseph M, Peat N, Russell B, Van Hemelrijck M. Is there a role for physical activity when treating patients with cancer with immune checkpoint inhibitors? Protocol for a scoping review. BMJ Open. 2021 Oct 8;11(10):e046052.
  • Man F, Koers A, Karagiannis P, Josephs DH, Bax HJ, Gilbert AE, Dodev TS, Mele S, Chiaruttini G, Crescioli S, Chauhan J, Blower JE, Cooper MS, Spicer J, Karagiannis SN, Blower PJ. In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart. Oncoimmunology. 2021 Sep 6;10(1):1966970.
  • McCraw AJ, Chauhan J, Bax HJ, Stavraka C, Osborn G, Grandits M, López-Abente J, Josephs DH, Spicer J, Wagner GK, Karagiannis SN, Chenoweth A, Crescioli S. Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments. Cancers (Basel). 2021 Sep 4;13(17):4460.
  • Santaolalla A, Sollie S, Rislan A, Josephs DH, Hammar N, Walldius G, Garmo H, Karagiannis SN, Van Hemelrijck M. Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study. BMC Immunol. 2021 Sep 6;22(1):61.
  • Roulstone V, Mansfield D, Harris RJ, Twigger K, White C, de Bono J, Spicer J, Karagiannis SN, Vile R, Pandha H, Melcher A, Harrington K. Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. J Immunother Cancer. 2021 Jul;9(7):e002673.
  • Harris RJ, Cheung A, Ng JCF, Laddach R, Chenoweth AM, Crescioli S, Fittall M, Dominguez-Rodriguez D, Roberts J, Levi D, Liu F, Alberts E, Quist J, Santaolalla A, Pinder SE, Gillett C, Hammar N, Irshad S, Van Hemelrijck M, Dunn-Walters DK, Fraternali F, Spicer JF, Lacy KE, Tsoka S, Grigoriadis A, Tutt ANJ, Karagiannis SN. Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. Cancer Res. 2021 Aug 15;81(16):4290-4304.
  • Amiri Souri E, Chenoweth A, Cheung A, Karagiannis SN, Tsoka S. Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer. Br J Cancer. 2021 Aug;125(5):748-758.
  • Pellizzari G, Martinez O, Crescioli S, Page R, Di Meo A, Mele S, Chiaruttini G, Hoinka J, Batruch I, Prassas I, Grandits M, López-Abente J, Bugallo-Blanco E, Ward M, Bax HJ, French E, Cheung A, Lombardi S, Figini M, Lacy KE, Diamandis EP, Josephs DH, Spicer J, Papa S, Karagiannis SN. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. J Immunother Cancer. 2021 Jun;9(6):e002140.
  • Runbeck E, Crescioli S, Karagiannis SN, Papa S. Utilizing Immunocytokines for Cancer Therapy. Antibodies (Basel). 2021 Mar 9;10(1):10.
  • Jordakieva G, Bianchini R, Reichhold D, Piehslinger J, Groschopf A, Jensen SA, Mearini E, Nocentini G, Crevenna R, Zlabinger GJ, Karagiannis SN, Klaus A, Jensen-Jarolim E. IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer. Oncoimmunology. 2021 Feb 8;10(1):1880687.
  • Willsmore ZN, Harris RJ, Crescioli S, Hussein K, Kakkassery H, Thapa D, Cheung A, Chauhan J, Bax HJ, Chenoweth A, Laddach R, Osborn G, McCraw A, Hoffmann RM, Nakamura M, Geh JL, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Papa S, Barber L, Lacy KE, Karagiannis SN. B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. Front Immunol. 2021 Jan 25;11:622442.
  • Abdul-Jawad S, Baù L, Alaguthurai T, Del Molino Del Barrio I, Laing AG, Hayday TS, Monin L, Muñoz-Ruiz M, McDonald L, Francos Quijorna I, McKenzie D, Davis R, Lorenc A, Chan JNE, Ryan S, Bugallo-Blanco E, Yorke R, Kamdar S, Fish M, Zlatareva I, Vantourout P, Jennings A, Gee S, Doores K, Bailey K, Hazell S, De Naurois J, Moss C, Russell B, Khan AA, Rowley M, Benjamin R, Enting D, Alrifai D, Wu Y, Zhou Y, Barber P, Ng T, Spicer J, Van Hemelrijck M, Kumar M, Vidler J, Lwin Y, Fields P, Karagiannis SN, Coolen ACC, Rigg A, Papa S, Hayday AC, Patten PEM, Irshad S. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell. 2021 Feb 8;39(2):257-275.e6.
  • Willsmore ZN, Coumbe BGT, Crescioli S, Reci S, Gupta A, Harris RJ, Chenoweth A, Chauhan J, Bax HJ, McCraw A, Cheung A, Osborn G, Hoffmann RM, Nakamura M, Laddach R, Geh JLC, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Josephs DH, Papa S, Lacy KE, Karagiannis SN. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. Eur J Immunol. 2021 Mar;51(3):544-556.
  • Pranger CL, Fazekas-Singer J, Köhler VK, Pali-Schöll I, Fiocchi A, Karagiannis SN, Zenarruzabeitia O, Borrego F, Jensen-Jarolim E. PIPE-cloned human IgE and IgG4 antibodies: New tools for investigating cow's milk allergy and tolerance. Allergy. 2021 May;76(5):1553-1556.